Neural Signatures and Cognitive Performance During Rat Morphine Withdrawal, and Subsequent Impact of Psilocybin
Project Number5F31DA059250-02
Contact PI/Project LeaderHONES, VICTORIA IVANOVA
Awardee OrganizationUNIVERSITY OF WASHINGTON
Description
Abstract Text
PROJECT ABSTRACT
Opioid addiction is pervasive and widespread, affecting roughly three million U.S. adults. Currently available
opioid addiction treatments, such as opioid replacement therapy, fail to slow the growing opioid pandemic and
maintain the risk of addiction and overdose. Moreover, available opioid addiction treatments require long-term
commitment to treatment with little evidence of long-lasting abstinence. Lastly, opioid replacement therapy is
unable to alleviate addiction-induced cognitive impairments. A deeper understanding of the neural and
cognitive systems that underlie addiction is necessary for the development of better targeted treatments for
opioid addiction.
The rodent model of opioid addiction exhibits behavioral markers analogous to those induced in human opioid
addiction. Hence, this is a reliable and feasible model for studies of the neural correlates of addiction-related
maladaptive behaviors. An emerging body of research suggests that the evolutionarily conserved lateral
habenula in rodents is highly implicated in addiction. The lateral habenula is unique in that it directly regulates
dopaminergic and serotonergic structures, both of which exhibit dysfunction in addiction. However, with
traditional electrophysiological methods of recording lateral habenula neural activity, it has been difficult to
clearly assess responses of large populations of neurons. More recent advances in imaging technology have
allowed for week-long monitoring of individual neuron calcium dynamics, easing the feasibility of studying the
lateral habenula neural responses. Serotonin agonists, such as psilocybin, have shown promising results in
reducing the rates of relapse in alcohol and nicotine addiction and improving cognitive function in unhealthy
adults. Importantly, lateral habenula hyperactivity is known to drive aversion and is present in withdrawal.
Serotonergic agonists have also been shown to quiet lateral habenula activity, suggesting a potential
unexplored treatment avenue.
Hence, with the use of calcium imaging, I hypothesize that lateral habenula neuron dynamics will shift to a
hyperactive state following morphine withdrawal, and that these neural signatures will correlate with
decreased performance on cognitive tasks. Additionally, I hypothesize that psilocybin treatment will reinstate
baseline lateral habenula activity and improve cognitive performance. The proposed series of experiments will
fill the gap in understanding the neural circuitry that drives maladaptive decisions during opiate withdrawal, as
well as the behavioral and neural effect of a novel treatment for opiate addiction.
Public Health Relevance Statement
PROJECT NARRATIVE
Opioid addiction is a growing pandemic that lacks treatment capable of producing long-lasting abstinence. This
project aims to examine the role of individual lateral habenula neurons in memory and cognitive flexibility
using calcium imaging methods in freely behaving rats undergoing opioid addiction and withdrawal.
Uncovering individual neuron contributions to the processes underlying addiction, as well as the neural and
behavioral response to psilocybin, will generate greater understanding of the basic neural mechanisms
underlying cognition and how these mechanisms become dysfunctional during opioid addiction.
No Sub Projects information available for 5F31DA059250-02
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5F31DA059250-02
Patents
No Patents information available for 5F31DA059250-02
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5F31DA059250-02
Clinical Studies
No Clinical Studies information available for 5F31DA059250-02
News and More
Related News Releases
No news release information available for 5F31DA059250-02
History
No Historical information available for 5F31DA059250-02
Similar Projects
No Similar Projects information available for 5F31DA059250-02